crizotinib
Also known as (R)-crizotinib, PF 2341066, PF-02341066, PF-2341066, PF2341066, Xalkori®
Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.
Research
3,920 papers- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.The New England journal of medicine · 2013
- Crizotinib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2018
- Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
- Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion.Autophagy · 2024
via PubMed
Article
10 sectionsContents
- Medical uses
- Mechanism of action
- Society and culture
- Legal status
- Research
- Lung cancer
- Lymphomas
- Other cancers
- References
- External links
Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.
== Medical uses == Crizotinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) or relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Connections
Categories
2-Aminopyridines4-Piperidinyl compoundsChlorobenzene derivativesCYP3A4 inhibitorsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by MerckDrugs developed by PfizerDrugs with non-standard legal statusECHA InfoCard ID from WikidataEthersFluorobenzene derivatives